Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

Lawrence Alan LeiterBertrand CariouDirk Müller-WielandHelen M ColhounStephano Del PratoFrancisco J TinahonesKausik K RayMaja Bujas-BobanovicCatherine DomengerJonas MandelRita SamuelRobert R Henry

Published in: Diabetes, obesity & metabolism (2017)

Alirocumab produced significant LDL cholesterol reductions in participants with insulin-treated diabetes regardless of diabetes type, and was generally well tolerated. Concomitant administration of alirocumab and insulin did not raise any safety concerns (NCT02585778).

Keyphrases

type diabetes
glycemic control
low density lipoprotein
cardiovascular disease
insulin resistance
weight loss
adipose tissue
metabolic syndrome
skeletal muscle